When did XILIO THERAPEUTICS INC (XLO) report earnings last quarter?
XILIO THERAPEUTICS INC (XLO) last reported earnings on 3/23/2026.
XILIO THERAPEUTICS INC (XLO) Earnings History & Surprises
NASDAQ:XLO • US98422T1007
Current stock price
8.51 USD
+0.03 (+0.35%)
Last:
XLO Earnings overview
Past quarterly earnings results for XILIO THERAPEUTICS INC (XLO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$1.98
- Revenue Estimate
- 6.969M
Last Reported
Most Recent- Release Date
- Mar 23, 2026
- Period
- Q4 / 2025
- EPS Reported
- $0.81
- EPS Surprise
- 147.74%
- Revenue Surprise
- 70.22%
Beat Rate
Last 8 Quarters 25%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.81 | -1.70 | 147.74% | 128.93% | 13.686M | 8.04M | 70.22% | 693.85% |
| Q3 2025 | -0.08 | -0.42 | 80.20% | 97.27% | 19.066M | 18.821M | 1.30% | 742.51% |
| Q2 2025 | -2.24 | -1.13 | -98.02% | 33.33% | 8.084M | 8.292M | -2.51% | 242.98% |
| Q1 2025 | -2.52 | 1.34 | -287.60% | 68.97% | 2.93M | 4.444M | -34.07% | - |
| Q4 2024 | -2.80 | -3.06 | 8.61% | 68.75% | 1.724M | 3.333M | -48.27% | - |
| Q3 2024 | -3.08 | -3.49 | 11.70% | 63.93% | 2.263M | 3.333M | -32.10% | - |
| Q2 2024 | -3.36 | -3.25 | -3.31% | 65.71% | 2.357M | 30.3M | -92.22% | - |
| Q1 2024 | -8.12 | -1.56 | -422.05% | 30.12% | 30.3M | -100.00% | - | |
| Q4 2023 | -8.96 | -9.05 | 0.99% | 21.95% | - | - | ||
| Q3 2023 | -8.54 | -11.42 | 25.21% | 15.28% | - | - | ||
| Q2 2023 | -9.80 | -12.27 | 20.11% | 22.22% | - | - | ||
| Q1 2023 | -11.62 | -12.52 | 7.22% | -6.41% | - | - | ||
| Q4 2022 | -11.48 | -11.10 | -3.42% | 16.33% | - | - | ||
| Q3 2022 | -10.08 | -12.41 | 18.76% | 96.61% | - | - | ||
| Q2 2022 | -12.60 | -11.04 | -14.10% | - | - | - | ||
| Q1 2022 | -10.92 | -13.13 | 16.80% | - | - | - | ||
| Q4 2021 | -13.72 | -16.49 | 16.80% | - | - | - | ||
| Q3 2021 | -297.78 | -22.59 | -1,218.27% | - | - | - | ||
| Q2 2021 | - | - | - | - | ||||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-74.20%
Max EPS beat (4)
80.20%
Min EPS beat (4)
-287.60%
Revenue beat statistics
Revenue beat (4)
1
Average Revenue beat (4)
-20.89%
Max Revenue beat (4)
1.30%
Min Revenue beat (4)
-48.27%
Analysis
In the last 4 quarters, XLO has beaten EPS estimates in 2 out of 4 releases
XLO has beaten revenue estimates in 1 out of the last 4 releases
In the last 4 quarters, XLO reported -74.2% below the EPS estimates on average.
In the last 4 quarters, XLO reported -20.9% below the revenue estimates on average.
Related analysis
XILIO THERAPEUTICS INC / XLO Earnings FAQ
Can you provide information on whether XILIO THERAPEUTICS INC beat earnings estimates in the last quarter?
XILIO THERAPEUTICS INC (XLO) beat EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does XLO stock beat earnings estimates?
In the last 4 quarters, XILIO THERAPEUTICS INC (XLO) has beaten EPS estimates in 2 out of 4 releases.